A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

PHASE2CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

September 30, 2012

Study Completion Date

April 30, 2014

Conditions
Melanoma
Interventions
DRUG

Ipilimumab

Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation

Trial Locations (58)

1070

Local Institution, Brussels

1090

Local Institution, Vienna

Local Institution, Brussels

1200

Local Institution, Brussels

2199

Local Institution, Johannesburg

7570

Local Institution, Cape Town

8000

Local Institution, Aarhus C

10065

Memorial Sloan Kettering Cancer Center, New York

16132

Local Institution, Genova

17210

Local Institution, Jaú

28203

Carolinas Medical Center, Charlotte

29010

Local Institution, Málaga

29200

Local Institution, Brest

29615

Cancer Centers Of The Carolinas, Greenville

32207

Baptist Cancer Institute, Jacksonville

45219

The Christ Hospital Cancer Center Research, Cincinnati

46009

Local Institution, Valencia

46202

Indiana Oncology Hematology Consultants, Indianapolis

47014

Local Institution, Meldola (Fc)

47900

Local Institution, Rimini

49044

Local Institution, Dnipro

53100

Local Institution, Siena

54511

Local Institution, Vandœuvre-lès-Nancy

60637

University Of Chicago, Chicago

63110

Washington University School Of Medicine, St Louis

64239

Local Institution, Tel Aviv

64507

St Joseph Oncology Inc, Saint Joseph

69120

Local Institution, Heidelberg

69373

Local Institution, Lyon

75010

Local Institution, Paris

75230

Center For Oncology Research & Treatment, P.A., Dallas

79410

Joe Arrington Cancer Research And Treatment Center, Lubbock

85719

University Of Arizona Cancer Center, Tucson

90025

The Angeles Clinic & Research Inst., Los Angeles

90033

Usc/Norris Comprehensive Cancer Center, Los Angeles

90050

Local Institution, Porto Alegre

90553

Local Institution, Lodz

90610

Local Institution, Porto Alegre

91120

Local Institution, Jerusalem

91750

Wilshire Oncology Medical Group Inc, Laverne

94115

San Francisco Oncology Associates, San Francisco

97213

Providence Portland Medical Center, Portland

98109

University Of Washington Medical Center, Seattle

191104

Local Institution, Saint Petersburg

355047

Local Institution, Stavropol

394000

Local Institution, Voronezh

Unknown

Local Institution, To Come

CP1280AEB

Local Institution, Buenos Aires

A-4600

Local Institution, Wels

T2N 4N2

Local Institution, Calgary

T6G 1Z2

Local Institution, Edmonton

E1C 6Z8

Local Institution, Moncton

775 20

Local Institution, Olomouc

D-12200

Local Institution, Berlin

D-24105

Local Institution, Kiel

0310

Local Institution, Oslo

61-866

Local Institution, Poznan

51-124

Local Institution, Wroclaw

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00162123 - A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | Biotech Hunter | Biotech Hunter